Key Drivers
- Liquidity Strength
- Cash Flow Weakness
- Profit Volatility
AIAI Summary
ABUS is now best viewed as a cash-rich, event-driven patent monetization story—not a self-sustaining biotech—so the investment hinges on converting the Moderna/Pfizer legal path into recurring cash while imdusiran remains only a long-dated option, with current valuation still constrained by nonrecurring earnings quality and binary legal outcomes.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •Cash Flow Weakness
- •Profit Volatility
ABUS looks financially strong on liquidity and leverage with a recent profit surge, but weak cash conversion and a poor full-year loss history make the improved valuation potentially fragile.
Price Behavior
Key Price Behavior Insights:
- •Support defense
- •Rebound stalled
- •Lower close
Over the last month, ABUS traded choppily and slipped from $4.68 to $4.24, so the key test is whether it can hold $4.13-$4.20 and reclaim $4.39-$4.42.
Choppy trade slipped about 9% from $4.68 to $4.24
Sentiment & News
Key News Insights:
- •Settlement-driven revenue
- •Licensing income
- •Corporate update
Arbutus' Q1 2026 results showed $179.1 million in revenue, driven mainly by estimated license income from a Moderna-related litigation settlement, highlighting the outsized impact of legal and licensing proceeds.
The results are likely supportive for Arbutus shares in the near term, but investors may view the revenue as one-time rather than recurring
Similar Companies in Healthcare
Other companies in the same sector with AI ratings